2. Search Result
Search Result
Results for "

HK-2

" in MedChemExpress (MCE) Product Catalog:

62

Inhibitors & Agonists

1

Fluorescent Dye

6

Peptides

1

Inhibitory Antibodies

13

Natural
Products

3

Recombinant Proteins

8

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1352
    L-Ornithine
    Maximum Cited Publications
    9 Publications Verification

    (S)-2,5-Diaminopentanoic acid

    		 Arginase Endogenous Metabolite Metabolic Disease
    L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective [2].
    L-Ornithine
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    		 PROTACs Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1
  • HY-W017018
    L-Ornithine hydrochloride
    Maximum Cited Publications
    9 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    L-Ornithine hydrochloride is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine hydrochloride shows nephroprotective [2].
    L-Ornithine hydrochloride
  • HY-P2813
    Hirudin
    3 Publications Verification

    		 Thrombin Apoptosis Cardiovascular Disease Cancer
    Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
    Hirudin
  • HY-B0735A
    Fenoldopam mesylate
    4 Publications Verification

    Fenoldopam methanesulfonate; SKF-82526 mesylate

    		 Dopamine Receptor Apoptosis Cardiovascular Disease Cancer
    Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis [2] .
    Fenoldopam mesylate
  • HY-N7675
    Flavanomarein

    		NF-κB TGF-beta/Smad Syk Cardiovascular Disease Neurological Disease Metabolic Disease
    Flavanomarein is a substance with cytoprotective, anti-inflammatory and antioxidant activities, with a Ka of 3.064e-5 M against human Syk. Flavanomarein enhances the phosphorylation level of AKT, regulates the expression of PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2 and ICAD, and inhibits the nuclear translocation of NF-κB p65. Flavanomarein regulates EMT marker proteins, promotes the proliferation of HK-2 cells, and protects neuronal cells from 6-OHDA-induced neurotoxic damage. Flavanomarein can be used in studies related to Parkinson's disease and diabetic nephropathy. [2]
    Flavanomarein
  • HY-175035
    HK-2-IN-1

    		Hexokinase Inflammation/Immunology Cancer
    HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer .
    HK-2-IN-1
  • HY-N0493
    Pectolinarigenin
    2 Publications Verification

    		 COX Lipoxygenase NF-κB p38 MAPK ERK HIF/HIF Prolyl-Hydroxylase Keap1-Nrf2 PI3K Apoptosis Autophagy Neurological Disease Inflammation/Immunology Cancer
    Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma [2] .
    Pectolinarigenin
  • HY-N2013
    Aristolactam I
    1 Publications Verification

    Aristololactam; Aristolactam

    		 Drug Metabolite Aquaporin Cadherin TGF-beta/Smad Endocrinology Cancer
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis [2] .
    Aristolactam I
  • HY-N2445
    Flavokawain C
    4 Publications Verification

    		 Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK Cancer
    Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer [2] .
    Flavokawain C
  • HY-172942
    SP11

    		Mitochondrial Metabolism Reactive Oxygen Species (ROS) Dynamin Cardiovascular Disease Infection Neurological Disease Cancer
    SP11 is a mitochondrial fission protein 1 (Fis1) inhibitor with an IC50 of 9.4 μM. SP11 binds only to activated Fis1 by engaging Cys41. SP11 preserves mitochondrial integrity and function during oxidative stress, inhibits hydrogen peroxide-induced mitochondrial ROS production, mitochondrial fragmentation, and Drp1 mitochondrial translocation. SP11 can be used for the research of parkinson’s disease .
    SP11
  • HY-120371
    CPUY192018
    1 Publications Verification

    		 Keap1-Nrf2 Apoptosis Reactive Oxygen Species (ROS) NF-κB Inflammation/Immunology
    CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, with an IC50 of 0.63 µM. CPUY192018 exhibits anti-inflammatory and antioxidant activities. CPUY192018 can activate the Nrf2-dependent antioxidant pathway and inhibit the NF-κB-related inflammatory response. CPUY192018 can be used in the research of inflammation-related diseases [2].
    CPUY192018
  • HY-155751
    HMGB1-IN-1

    		Interleukin Related TNF Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    HMGB1-IN-1 (compound 6) displays strong NO inhibitory effect in RAW264.7 cells with IC50 value of 15.9 ± 0.6 μM. HMGB1-IN-1 inhibit the HMGB1/NF-κB/NLRP3 pathway. HMGB1-IN-1 shows good anti-inflammatory activity and good anti-sepsis effects in kidney injury .
    HMGB1-IN-1
  • HY-W002942
    Ferroptosis-IN-21

    1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline

    		 Ferroptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .
    Ferroptosis-IN-21
  • HY-N0909
    Notoginsenoside R2
    1 Publications Verification

    20(S)-Notoginsenoside R2; Ginsenoside Ng-R2

    		 Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT Neurological Disease Metabolic Disease Inflammation/Immunology
    Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis [2] .
    Notoginsenoside R2
  • HY-125938
    Cycloartenyl ferulate
    1 Publications Verification

    Cycloartenol ferulate; Cycloartenol ferulic acid ester

    		 Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT Inflammation/Immunology Cancer
    Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity Kd = 0.5 μM) to activate the canonical JAK1/2-STAT1 signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention [2] .
    Cycloartenyl ferulate
  • HY-122615B
    SPOP-IN-6b dihydrochloride
    3 Publications Verification

    		 E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b dihydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b dihydrochloride
  • HY-P5314
    OK2

    		EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-173414
    PROTAC STING degrader-3

    		PROTACs STING NF-κB Inflammation/Immunology
    PROTAC STING degrader-3 is a STING PROTAC degrader (DC50: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) .
    PROTAC STING degrader-3
  • HY-168717
    HK-2-IN-2

    		Hexokinase Microtubule/Tubulin Reactive Oxygen Species (ROS) Cancer
    HK2-IN-2 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. HK2-IN-2 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .
    HK-2-IN-2
  • HY-130437
    p-nitro-Pifithrin-α

    		MDM-2/p53 TGF-β Receptor Caspase Infection Metabolic Disease
    p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease [2] .
    p-nitro-Pifithrin-α
  • HY-156277
    SP4f

    		PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-126710
    OU749

    		γ-Glutamyl Transferase (GGT) Cancer
    OU749 is a potent γ-glutamyl transpeptidase (GGT) inhibitor with a Ki value of 17.6 µM. OU749 shows cytotoxicity .
    OU749
  • HY-W017018R
    L-Ornithine hydrochloride (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    L-Ornithine (hydrochloride) (Standard) is the analytical standard of L-Ornithine (hydrochloride). This product is intended for research and analytical applications. L-Ornithine hydrochloride is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine hydrochloride shows nephroprotective [2].
    L-Ornithine hydrochloride (Standard)
  • HY-RS16576
    Hk2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hk2 Mouse Pre-designed siRNA Set A
    Hk2 Mouse Pre-designed siRNA Set A
  • HY-RS06193
    HK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HK2 Human Pre-designed siRNA Set A contains three designed siRNAs for HK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HK2 Human Pre-designed siRNA Set A
    HK2 Human Pre-designed siRNA Set A
  • HY-172400
    FXIa-IN-16

    		Factor XI Cardiovascular Disease
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .
    FXIa-IN-16
  • HY-N2891
    Aristolactam A II

    Aristololactam A II

    		 Parasite COX Infection
    Aristolactam A II (Aristololactam A II) is a weak COX inhibitor with cytotoxic and anti-plasmodial activities. Aristolactam A II exhibits inhibitory activity against Chloroquine (HY-17589A)-sensitive strains, and exerts its inhibitory effect on Plasmodium falciparum growth by inducing cell membrane damage marked by LDH release. Aristolactam A II can be applied to the research of malaria-related mechanisms [2] .
    Aristolactam A II
  • HY-RS23009
    Hk2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hk2 Rat Pre-designed siRNA Set A
    Hk2 Rat Pre-designed siRNA Set A
  • HY-156276
    SP4e

    		PPAR Metabolic Disease
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4e
  • HY-156368
    RIPK3-IN-4

    		RIP kinase Inflammation/Immunology
    RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .
    RIPK3-IN-4
  • HY-N0401B
    (E)-Ligustilide

    		Others Metabolic Disease
    (E)-Ligustilide is isolated from Angelica?sinensis and has nephroprotective?effects .
    (E)-Ligustilide
  • HY-122615A
    SPOP-IN-6b hydrochloride

    		E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b hydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b hydrochloride
  • HY-182243
    HK2-IN-4

    		Hexokinase VDAC Apoptosis AMPK Bcl-2 Family Cancer
    HK2-IN-4 is a selective hexokinase 2 (HK2) inhibitor with an IC50 value of 0.79 μM and a Kd value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 (VDAC1). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis (apoptosis) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer .
    HK2-IN-4
  • HY-180805
    HK2-IN-3

    		Hexokinase Mitophagy Apoptosis GLUT Cancer
    HK2-IN-3 (compound 12) is a potent hexokinase 2 (HK2) inhibitor with an IC50 of 56.4 nM. HK2-IN-3 reduces glucose uptake and downregulated GLUT1/GLUT4 in oral squamous cell carcinoma (OSCC). HK2-IN-3 induces mitophagy and apoptosis. HK2-IN-3 suppresses tumor growth and angiogenesis in OSCC xenograft mouse models. HK2-IN-3 can be used for OSCC research .
    HK2-IN-3
  • HY-179378
    XRF-1021

    		DYRK TGF-beta/Smad NF-κB Wnt β-catenin MDM-2/p53 Notch Inflammation/Immunology
    XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM). XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease .
    XRF-1021
  • HY-P991808
    Anti-Mouse CD90 Antibody (HK2.1)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD90 Antibody (HK2.1) reacts with the mouse CD90. Anti-Mouse CD90 Antibody (HK2.1) has been implicated in activation of T-cells. Recommend Isotype Controls: Rat IgG2c .
    Anti-Mouse CD90 Antibody (HK2.1)
  • HY-RS06288
    HOOK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HOOK2 Human Pre-designed siRNA Set A contains three designed siRNAs for HOOK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HOOK2 Human Pre-designed siRNA Set A
    HOOK2 Human Pre-designed siRNA Set A
  • HY-RS07282
    KIF2A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KIF2A Human Pre-designed siRNA Set A contains three designed siRNAs for KIF2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KIF2A Human Pre-designed siRNA Set A
    KIF2A Human Pre-designed siRNA Set A
  • HY-RS07380
    KLK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for KLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KLK2 Human Pre-designed siRNA Set A
    KLK2 Human Pre-designed siRNA Set A
  • HY-RS07101
    KCNA5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KCNA5 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KCNA5 Human Pre-designed siRNA Set A
    KCNA5 Human Pre-designed siRNA Set A
  • HY-183809
    ZSW

    		Hexokinase Inflammation/Immunology
    ZSW is a hexokinase 2 (HK2) inhibitor with human HK2 IC50 of 0.48 μM, human HK2 Ka of 252.00 μM, and selectivity over HK3 and GCK. ZSW binds directly to HK2, inhibits its enzymatic activity, modulates macrophage phenotypes through glycolysis inhibition, and inhibits NF-κB nuclear translocation by preventing IκBα phosphorylation and degradation. ZSW alleviates inflammatory bowel disease (IBD) and improves the intestinal inflammatory state of IBD mice. ZSW can be used for the research of inflammatory bowel disease .
    ZSW
  • HY-173024
    TRPC4/5-IN-3

    		TRP Channel Neurological Disease
    TRPC4/5-IN-3 (Compound 32) is the orally active inhibitor for transient receptor potential canonical channel 4/5 (TRPC4/5) with IC50 of 3.6 nM and 5.5 nM. TRPC4/5-IN-3 inhibits hERG channel with IC50 of 6.5 µM. TRPC4/5-IN-3 exhibits good metabolic stability in human/rat/mouse liver microsomes. TRPC4/5-IN-3 exhibits antidepressant and anxiolytic activity in mouse models, exhibits good pharmacokinetic characteristics in mouse with an oral bioavailability of 87% .
    TRPC4/5-IN-3
  • HY-123409
    Nicousamide

    		TGF-β Receptor Metabolic Disease
    Nicousamide is a potent inhibitor of TGF-β RII phosphorylation. Nicousamide can be used to study renal fibrosis in animal models of diabetic nephropathy .
    Nicousamide
  • HY-146560
    Xanthine oxidase-IN-6

    		Xanthine Oxidase NF-κB Toll-like Receptor (TLR) TNF Receptor Metabolic Disease Inflammation/Immunology
    Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an IC50 value of 1.37 µM. Xanthine oxidase-IN-6 shows strong anti-hyperuricemia and renal protective activity .
    Xanthine oxidase-IN-6
  • HY-110021
    Fenoldopam hydrochloride

    SKF 82526 hydrochloride

    		 Dopamine Receptor Histone Demethylase Apoptosis Cardiovascular Disease Cancer
    Fenoldopam (SKF 82526) hydrochloride is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis [2] .
    Fenoldopam hydrochloride
  • HY-172600
    TRPC6 antagonist-1

    		TRP Channel Inflammation/Immunology
    TRPC6 antagonist-1 (X26) is a TRPC6 antagonist with IC50 values of 0.97 μM, 3.93 μM, 5.77 μM and 4.37 μM for TRPC6, TRPC3, TRPC5 and TRPC7, respectively. TRPC6 antagonist-1 inhibits TGF-β1-induced myofibroblast differentiation, and attenuates renal fibrosis .
    TRPC6 antagonist-1
  • HY-151544
    PNE-Lyso

    		Fluorescent Dye Others
    PNE-Lyso is a activatable fluorescent probe. PNE-Lyso can be used to detect intracellular pH and hexosaminidases with two kinds of fluorescence signals. PNE-Lyso can be used to distinguish apoptosis from necrosis through visualizing lysosome morphology. PNE-Lyso is capable of investigating the agent-induced cell death process .
    PNE-Lyso
  • HY-149053
    OY-101

    		P-glycoprotein Cancer
    OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .
    OY-101
  • HY-163748
    GSK-3β inhibitor 17

    		GSK-3 Inflammation/Immunology
    GSK-3β inhibitor 17 (compound 5 n) is a potent GSK-3β inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .
    GSK-3β inhibitor 17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: